Kuros Biosciences Ltd. (KURN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Basilea Pharmaceutica AG

Bachem Holding AG

BB Biotech AG

Kuros Biosciences Ltd.

Lonza Group AG

PolyPeptide Group AG

Idorsia Ltd.

Molecular Partners AG

RELIEF THERAPEUTICS Holding SA

Addex Therapeutics Ltd.

Why is Kuros Biosciences Ltd. ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of -44.92% and Operating profit at -0.77% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 38.89%, its profits have fallen by -234.4%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kuros Biosciences Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Kuros Biosciences Ltd.

37.63%

16.50

59.53%

Switzerland SMI

10.0%

0.63

15.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-44.92%

EBIT Growth (5y)

-0.77%

EBIT to Interest (avg)

-4.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.24

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

16.34

EV to EBIT

-48.89

EV to EBITDA

-49.05

EV to Capital Employed

19.83

EV to Sales

1237.98

PEG Ratio

Dividend Yield

ROCE (Latest)

-40.56%

ROE (Latest)

-40.21%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CHF -1.68 MM

NET SALES(Q)

Highest at CHF 63.48 MM

OPERATING PROFIT(Q)

Highest at CHF 5.04 MM

OPERATING PROFIT MARGIN(Q)

Highest at 7.95 %

RAW MATERIAL COST(Y)

Fallen by -9.07% (YoY

-12What is not working for the Company

NET PROFIT(Q)

At CHF -2.04 MM has Fallen at -864.93%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.26%

INTEREST(Q)

Highest at CHF 5.56 MM

PRE-TAX PROFIT(Q)

Fallen at -87.5%

Here's what is working for Kuros Biosciences Ltd.

Net Sales

Highest at CHF 63.48 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (CHF MM)

Net Sales

At CHF 63.48 MM has Grown at 99.35%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (CHF MM)

Operating Profit

Highest at CHF 5.04 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (CHF MM)

Operating Profit Margin

Highest at 7.95 % and Grown

In each period in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Operating Cash Flow

Highest at CHF -1.68 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CHF MM)

Raw Material Cost

Fallen by -9.07% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at CHF 1.55 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (CHF MM)

Depreciation

At CHF 1.55 MM has Grown at 19%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (CHF MM)

Here's what is not working for Kuros Biosciences Ltd.

Net Profit

At CHF -2.04 MM has Fallen at -864.93%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CHF MM)

Interest

Highest at CHF 5.56 MM

in the last five periods and Increased by 596.99% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CHF MM)

Pre-Tax Profit

Fallen at -87.5%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CHF MM)

Inventory Turnover Ratio

Lowest at 1.26%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio